Loading stock data…
LNSR
$5.69+0.09 (+1.61%)
After Hours$5.69+0.00 (+0.00%)· Last close Jun 9
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LENSAR, Inc. in the Healthcare sector is trading at $5.69. Wall Street consensus targets $8.50 (2 analysts), implying a +49.4% move over the next 12 months. The stock is currently near its 52-week low of $5.06, remaining 43.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +49.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.69
Potential Downside
0%
Whystock Fair Value$5.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
272.45%
Volume
Today's trading volume
22,261
Recent News
How The LENSAR (LNSR) Story Is Shifting After The Failed Deal And New $10 Target
The analyst price target for LENSAR has been set at $10, compared with an unchanged fair value estimate of $8.50 in the updated model. Bullish commentary links this $10 target to expectations that profitability and the ALLY System’s adoption can support that higher level, while more cautious views highlight execution and growth risks around the same figure. As you read on, you will see how these differing views are shaping the evolving story around LENSAR and what to watch next. Wall Street's...
Lensar (LNSR) Q1 2026 Earnings Transcript
Nick Curtis, Chief Executive Officer; and Tom Staab, Chief Financial Officer of LENSAR, who will provide an overview of recent developments, our go-forward strategy and financial results. Before we begin, I'd like to remind you all that today's call will contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information as well as information about the company's future performance and/or achievements. You should not place any undue reliance on these forward-looking statements.
Lensar (LNSR) Q4 2025 Earnings Transcript
Nick Curtis, Chief Executive Officer; and Tom Staab, Chief Financial Officer of LENSAR, who will provide an overview of recent developments, our go-forward strategy and our Q4 financial results. Before we begin, I'd like to remind you all that today's conference call will contain forward-looking statements, including statements regarding our future results, unaudited and forward-looking financial information as well as information on the company's future performance and/or achievements.
LENSAR Q1 Earnings Call Highlights
LENSAR (NASDAQ:LNSR) executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential
The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential upside. Supporters connect this $10 mark to their view that ALLY System adoption can return to patterns seen before the Alcon deal was announced, while skeptics question whether that setup already bakes in optimistic execution. As you read on, you will see how both the bullish...